Sun Pharma said it will acquire Japan-based Pola Pharma for around $1 million to strengthen its global dermatology presence.
Pola Pharma is engaged in research and development, manufacture, sale and distribution of branded and generic products — mostly dermatology products — in Japan. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations.
Sun Pharma entered the Japanese prescription market in 2016 with the acquisition of 14 established prescription brands from Novartis. The Pola transaction is expected to close on or before Jan 31, 2019.
Read the press release